BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES IN INDIA: A GENERIC OVERVIEW

Main Article Content

RAJESHWARI S. R.
BALAMURALIDHARA V.
RAMYASHREE G.

Abstract

In India generic drugs are distributed to public by retail shops as “JANAUSHADHA”. Generics are the drugs which are not branded but they are proven to be bioequivalent to branded drugs. Generic drugs must show similarity with its reference drug in terms of dosage form, strength, API and route of administration. Need of generic drugs in market is high as they are available at reasonable cost, the prime importance is to make the good quality drugs available at lower cost to public. The main objective of the study is to know the process of approval of generics, type of products eligible for BE study and the regulatory aspects for generic approval in India. The regulations for conduct of BA/BE studies in India is set up by Central Drugs Standard Control Organisation (CDSCO). The various regulatory aspects for the development of generic drugs, study design and parameters considered during study and the documentation required the concerned authority has been discussed. The new drug and clinical trial rules 2019 have bought new set of rules which is helpful in conducting BA/BE studies and clinical trials in support with ethical aspects. There is need of more specific guidelines for conduct of BA/BE studies in India for more reliability on generics.

Keywords:
Bioavailability (BA), bioequivalence (BE), abbreviated new drug application (ANDA), no objection certificate (NOC)

Article Details

How to Cite
R., R. S., V., B., & G., R. (2021). BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES IN INDIA: A GENERIC OVERVIEW. Journal of International Research in Medical and Pharmaceutical Sciences, 16(3), 22-32. Retrieved from https://www.ikprress.org/index.php/JIRMEPS/article/view/6801
Section
Review Article

References

Global Generic Drugs Market Analysis to 2026 - Vendors Covered Include Cipla, Novartis, Valeant & Baxter International Among Others - ResearchAndMarkets.com | Business Wire [Internet]. [Cited 2021 Jul 8].
Available:https://www.businesswire.com/news/home/20200327005404/en/Global-Generic-Drugs-Market-Analysis-to-2026---Vendors-Covered-Include-Cipla-Novartis-Valeant-Baxter-International-Among-Others---ResearchAndMarkets.com

Page not found - Express Pharma [Internet]. [Cited 2021 Jul 8].
Available:https://www.expresspharma.in/drug-approvals/anda-approvals-in-2019-trends-for-thegenerics-industry/

Global Generic Pharmaceuticals Market Data And Industry Growth Analysis [Internet]. [Cited 2021 Jul 8].
Available:https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Hatch-Waxman Letters | FDA [Internet]. [Cited 2021 Jul 8].
Available:https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters

Boehm G, Yao L, Han L, Zheng Q. Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984. Acta Pharm Sin B. 2013;3(5):297–311.

BA/BE [Internet]. [Cited 2021 Jul 8].
Available:https://cdsco.gov.in/opencms/opencms/en/bioequi_bioavail/index.html

Spurious Drugs: Whistleblowers to be Rewarded In India [Internet].
[Cited 2021 Jul 28].
Available:https://www.medindia.net/news/spurious-drugs-whistleblowers-to-be-rewarded-in-india-55139-1.htm

Miranda M, Sousa JJ, Veiga F, Cardoso C, Vitorino C. Bioequivalence of topical generic products. Part 1: Where are we now? Eur J Pharm Sci. 2018;123:260–7.

Nagadurga DH. Bioavailability and Bioequivalence Studies. Pharm Formul Des - Recent Pract [Internet]; 2019.
[Cited 2021 Jul 28].
Available:https://www.intechopen.com/chapters/66222

Home - PMC - NCBI [Internet]. [Cited 2021 Jul 28].
Available:https://www.ncbi.nlm.nih.gov/pmc/

NEW DRUG APPROVAL PROCEDURE IN INDIA | PharmaTutor [Internet]. [Cited 2021 Jul 27].
Available:https://www.pharmatutor.org/articles/new-drug-approval-procedure-india

Pre-Screening revised checklist for BA/BE NOC for Export Purpose O/o Drugs Controller General (India) Directorate General of Health Services FDA Bhawan, New Delhi (With effective from 25 th April 2014).

Nishith Desai Associates: Interim relief in foreign-seated arbitrations – Efficacious remedy and implied exclusion [Internet]. [Cited 2021 Jul 28].
Available:https://www.nishithdesai.com/information/research-and-articles/nda-hotline/nda-hotline-single-view/article/interim-relief-in-foreign-seated-arbitrations-efficacious-remedy-and-implied-exclusion.html

Home [Internet].
[Cited 2021 Jul 8].
Available:https://cdsco.gov.in/opencms/opencms/en/Home/

CDSCO issue guidance documents for Approval Of BA/BE NOC for Export Purpose | PharmaTutor [Internet].
[Cited 2021 Jul 28].
Available:https://www.pharmatutor.org/pharma-news/2018/cdsco-issue-guidance-documents-for-approval-of-ba-be-noc-for-export-purpose

Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India Frequently Asked Questions (FAQs) on New Drugs and Clinical Trials.

1500+ Best Company Vision and Mission Statements [by Industry] - Status Articles [Internet]. [Cited 2021 Jul 27].
Available:https://status.net/articles/best-company-slogans-vision-mission-statements-examples/

BE NOC for Export -CliniExperts [Internet]. [Cited 2021 Jul 8].
Available:https://cliniexperts.com/india-regulatory-services/drug/for-manufacturer/be-noc-for-export/

jftLVa h la ö Mhö ,yö&33004@99 Hkkx II-[k.M 3-mi&[k.M (i) PART II-Section 3-Sub-section (i).

Branded Medicines and Generic Medicines [Internet]. [Cited 2021 Jul 8].
Available:https://blog.pharmafranchisehelp.org/2019/08/branded-medicines-and-generic-medicines.html

D’Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol 2012 131 [Internet]. 2012;13(1):1–10. [Cited 2021 Jul 28].
Available:https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/2050-6511-13-14